leukemia

[Gene Therapy] CAR T cells were designed using a ligand binding domain instead of a single chain variable fragments to target stem-like leukemia cells. Thrombopoietin, the natural ligand to the myeloproliferative leukemia protein (MPL) receptor, was used as the antigen binding domain to engage MPL expressed on HSCs and erythropoietic and megakaryocytic acute myeloid leukemias.

[Leukemia] The increased stemness of acute myeloid leukemia (AML) cells promoted by Tregs was verified in vitro and in vivo, and researchers found that blocking the interaction between Tregs and AML cells may be a new approach to target leukemia stem cells in AML treatment.

[Nature Communications] Exploiting the mutational footprint of some chemotherapies, researchers explored their influence on the evolution of hematopoietic cells.

[npj Precision Oncology] Using in vitro models of JAK2r B-ALL, JAK2 p.G993A conferred resistance to six type-I JAK inhibitors and the type-II JAK inhibitor, CHZ-868.

[ScienceInsider] A clinical trial of a gene therapy for a rare neurological disease is on hold after a participant in the study developed a bone marrow disorder that can lead to leukemia, the trial’s sponsor, bluebird bio, announced.

[IN8bio, Inc.] IN8bio, Inc. announced completion of dosing of the first patient cohort in a Phase I clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant.